On March 24, China's first independently developed new type of tuberculosis mRNA vaccine launched a clinical trial in the Beijing Chest Hospital affiliated to Capital Medical University. The first 36 research participants were included in the first group to be vaccinated. Li Liang, vice president of the hospital, was the first research participant to be vaccinated. I have been waiting for this moment for too many years As a clinician who has been engaged in the diagnosis and treatment of tuberculosis for more than 30 years, Li Liang has always paid close attention to the research trend of mRNA vaccine. "I am very lucky to be the first research participant in this vaccine research experiment. I am very confident in this vaccine, and hope that in the near future, it can become an important tool to end tuberculosis." As one of the oldest infectious diseases in the world, tuberculosis is still threatening human health. At present, BCG vaccine, the only approved tuberculosis vaccine in the world, can prevent serious tuberculosis in infants and young children, but its protective effect on adolescents and adults is limited. The research and development of effective tuberculosis vaccine for adolescents and adults has become a difficult problem for researchers all over the world. In recent years, mRNA vaccines have become a new star in the field of vaccine development due to their significant advantages such as high safety and strong ability to induce specific immune responses Pang Yu, the head of vaccine research and development and director of the Bacterial Immunology Department at Beijing Chest Hospital, introduced that the team has gone through a lot of arduous and meticulous work, selecting 10 advantageous antigens from more than 20 candidate antigens metabolized by Mycobacterium tuberculosis through multiple pathways and combining them. Finally, they successfully screened three combinations with the best protective effect. Animal experiments have shown that the protective efficacy of this new mRNA vaccine is more than 20 times higher than that of BCG vaccine, demonstrating great potential. "If all goes well, this tuberculosis mRNA vaccine with independent intellectual property rights is expected to achieve clinical marketing." Pang Yu introduced that at that time, it will benefit more than 300 million people with latent infection of tuberculosis and 100 million people at risk of tuberculosis infection, and plans to promote vaccination to the whole population, which will effectively reduce the incidence rate and infection rate of tuberculosis, and control the spread of tuberculosis. In addition to the mRNA vaccine, the Beijing Chest Hospital also released the tuberculosis tongue swab detection technology, AI intelligent diagnosis model based on acoustic biomarkers, new anti tuberculosis drugs, and the nine month treatment plan for drug-resistant tuberculosis with Bedazoline on the same day. (New Society)